IRF2BP1

IRF2BP1 is a nuclear transcriptional co-repressor that controls gene expression through both direct repressor-complex assembly and RING-dependent enzymatic activity (PMID:12799427, PMID:21444724). It was originally defined by its specific interaction with the C-terminal repression domain of IRF-2, repressing both enhancer-activated and basal transcription independently of histone deacetylation, with conformational requirements in IRF-2 governing co-repressor recruitment (PMID:12799427). IRF2BP1 stabilizes and operates within the DIF-1 (IRF-2BP2) repressor complex together with IRF-2BP2 and EAP1 through conserved C4 zinc finger interactions, binding the FASTKD2 promoter to repress its transcription and thereby control apoptosis (PMID:21444724). Beyond scaffolding, its C-terminal RING finger confers E3 ubiquitin ligase activity toward JDP2, promoting JDP2 polyubiquitination and repressing ATF2-mediated transcription from CRE-containing promoters (PMID:18671972). Its repressive output is dynamically regulated: a transient deSUMOylation cycle downstream of EGF stimulation acts as a switch that relieves IRF2BP1 repression of the DUSP1 promoter to permit timely immediate-early gene transcription (DUSP1, ATF3) (PMID:33480129). IRF2BP1 also functions downstream of Cdk5 in an Irf2bp1-Stat1-importin α-Nlrc5 pathway that suppresses MHC-I expression in breast cancer brain metastasis, enabling immune evasion (PMID:39304713). It has additionally been identified as a RARA fusion partner in a variant acute promyelocytic leukemia (PMID:38410879).

1. 2003 High

   Established IRF2BP1 as a bona fide transcriptional co-repressor by defining its interaction with IRF-2 and its HDAC-independent repression mechanism, answering how IRF-2's repression domain executes transcriptional silencing.

   Evidence Co-immunoprecipitation, transcription reporter assays, nuclear localization imaging, and HDAC inhibitor experiments in cells

   PMID:12799427

   Open questions at the time

   • The molecular mechanism of HDAC-independent repression is undefined
   • No structural basis for the IRF-2 conformational requirement
   • Genome-wide target repertoire not mapped
2. 2008 Medium

   Revealed that the C-terminal RING finger is catalytically functional, showing IRF2BP1 acts as an E3 ubiquitin ligase for JDP2 and represses ATF2-dependent transcription, expanding its role beyond passive scaffolding to enzymatic regulation.

   Evidence Co-immunoprecipitation, in vitro/cell-based ubiquitination assay, and transcription reporter assay

   PMID:18671972

   Open questions at the time

   • Single lab without independent replication
   • Fate of ubiquitinated JDP2 (degradation vs. signaling) not resolved
   • Other RING substrates not identified
3. 2011 High

   Defined IRF2BP1 as a structural and functional member of the DIF-1/IRF-2BP2/EAP1 repressor complex assembled via C4 zinc finger interactions, linking it to FASTKD2 repression and apoptosis control in breast cancer.

   Evidence Reciprocal Co-IP, ChIP at the FASTKD2 promoter, microarray, RNAi knockdown with apoptosis readout, and zinc finger domain mapping

   PMID:21444724

   Open questions at the time

   • Whether IRF2BP1 contributes catalytic vs. scaffolding function within the complex is unclear
   • Full set of complex target genes not enumerated
   • Recruitment to specific promoters not mechanistically dissected
4. 2021 High

   Showed that IRF2BP1 repressive activity is dynamically controlled by a SUMOylation cycle downstream of EGFR, identifying transient deSUMOylation as the switch permitting immediate-early gene transcription.

   Evidence Quantitative SUMO proteomics before/after EGF stimulation, SUMOylation-deficient mutant analysis, and immediate-early gene expression assays

   PMID:33480129

   Open questions at the time

   • The SUMO E3/protease enzymes acting on IRF2BP1 are not identified
   • How SUMO state mechanistically alters repressor function is unknown
   • Generality beyond DUSP1/ATF3 not established
5. 2024 Medium

   Placed IRF2BP1 within a defined Cdk5-Irf2bp1-Stat1-importin α-Nlrc5 epistatic pathway that suppresses MHC-I, connecting its repressor function to immune evasion in brain metastasis.

   Evidence Single-cell RNA-seq, genetic/pharmacological Cdk5 inhibition, MHC-I/antigen-presentation assays, and pathway epistasis in mouse brain metastasis models

   PMID:39304713

   Open questions at the time

   • Direct molecular target of IRF2BP1 in this pathway not defined
   • Whether RING ligase activity is required is untested
   • Single study without independent replication
6. 2024 Low

   Identified IRF2BP1 as a RARA fusion partner in variant APL, raising the possibility of an oncogenic fusion role, though the fusion protein's function was not characterized.

   Evidence Molecular characterization of fusion breakpoints and transcript by sequencing in a single APL case

   PMID:38410879

   Open questions at the time

   • Single case report with no functional characterization of the fusion protein
   • Transforming activity untested
   • Contribution of IRF2BP1 portion to leukemogenesis unknown

• How IRF2BP1's distinct activities — scaffolding within the DIF-1 complex, RING E3 ligase function, and SUMO-gated repression — are integrated and selectively deployed at different target genes remains unresolved.
• No structural model linking zinc finger, RING, and SUMO sites
• Genome-wide direct target map absent
• Relationship between catalytic and scaffolding roles undefined